Appointment dossier — Ovarian Rhabdomyosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Rhabdomyosarcoma
- Cyclophosphamide — Review evidence · 1 positive · PMID 18004572, 41474586
- Doxorubicin — Review evidence · 1 positive · PMID 18004572
- Vincristine — Review evidence · 1 positive · PMID 18004572, 41474586
- Actinomycin D — Review evidence · 0 positive · PMID 41474586
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT04657068 · Phase 1 / Phase 2 — A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (United States)
- NCT06730347 · Phase 2 — A Study of Lorigerlimab in Participants With Advanced Solid Tumors (United States)
- NCT06399757 · Phase 1 / Phase 2 — A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (United States)
- NCT05005403 · Phase 1 — Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (United States)
- NCT05799274 · Phase 1 — Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors (United States)
- NCT06508307 · Phase 1 — A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors (China)
- NCT06451497 · Phase 1 — This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (United States)
- NCT07326111 · Phase 4 — A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese (Germany)
- NCT06412510 · Phase 1 / Phase 2 — Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (United States)
- NCT07182526 · Phase 2 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome (Iraq)
- NCT03983226 · Phase 2 — Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) (China)
- NCT07042802 · Phase 1 / Phase 2 — A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer (China)
- NCT06686030 · Phase 2 — Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer (China)
- NCT07030907 · Phase 1 — A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (United States)
- NCT04811703 · Phase 1 — Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (France)
- NCT03050268 — Familial Investigations of Childhood Cancer Predisposition (United States)
- NCT05440617 — Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy (United States)
- NCT05990426 — Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy (United States)
Most-relevant first: trials that name Ovarian Rhabdomyosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Has my tumor been tested for Desmin / myogenin / MyoD1, and would the result open up targeted treatments or trials?
- Has my tumor been tested for PAX3–FOXO1 / PAX7–FOXO1, and would the result open up targeted treatments or trials?
- Has my tumor been tested for DICER1, and would the result open up targeted treatments or trials?
- Of the open trials I found (for example NCT04657068), am I eligible for any — here or at a larger cancer center?
- Which RMS subtype do I have (embryonal, alveolar, spindle/sclerosing, pleomorphic) and how does it change treatment?
- Is fertility-sparing surgery possible and safe in my case?
- Which chemo backbone is recommended for my age and subtype?
- Do I need radiation for margin-positive or nodal disease?
- Are there trials matched to my tumor’s drivers (e.g., PAX–FOXO1, PI3K/AKT/mTOR, MSI)?
- Can we send tissue for RNA fusion panel and DNA NGS now, and again at progression to capture targets (e.g., TFCP2, FGFR4, ALK)?
- Do we have enough banked tumor (FFPE + fresh-frozen) and a recent biopsy to qualify for molecular trials?
- What is the plan if there’s inadequate response after 2–3 cycles—what are our pre-agreed switch criteria?
- Am I a candidate for neoadjuvant therapy to improve the chance of an R0 resection?
- If disease is limited, could metastasectomy, ablation, or SBRT consolidate a systemic response?
- Would anthracycline cardioprotection (dexrazoxane) help preserve intensity without compromising efficacy?
- Should we involve a sarcoma specialty center or enroll via a national consortium (SARC, EORTC, NCI)?
- Are there basket trials for my biomarkers (FGFR4, ALK, NTRK, BET/BRD4, YAP/TEAD, MDM2)?
- Could we combine targeted agents with RT or chemo on a protocol to blunt resistance feedback (e.g., PI3K/mTOR + MEK)?
- What’s our VTE prevention plan and symptom-triggered pathway for urgent evaluation?
- How will we monitor for cardiac, renal, and neurotoxicity, and what dose-modification rules protect outcomes?
- Do I qualify for compassionate use / expanded access if a matched trial isn’t available?
- Is there a role for ctDNA as an adjunct to imaging for trend-tracking in my case?